Forbes March 2, 2022
Seth Joseph

An in-depth look at Surescripts’ partnership with GoodRx raises a number of questions about the deal, why it was done, and who stands to benefit now and in the long term. 

What happens when two organizations join forces on the promise of delivering pricing transparency for the nation…except instead of price transparency, what’s delivered is price obfuscation? 

On August 5, 2021, GoodRx and Surescripts announced an agreement to incorporate GoodRx drug coupons into Surescripts’ Real-Time Prescription Benefit (RTPB) service. Through the partnership, GoodRx’s drug discount pricing information is made available to prescribers at the point of care, when they are writing a prescription in their electronic health record (EHR). The partnership generated a fair amount of media attention at the...

Today's Sponsors

Institute for Healthcare Improvement
Crossover Health
Qure4u

Today's Sponsors

Patient Bond
pCare

Today's Sponsor

pCare

 
Topics: Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
ICER’s 2022 “Barriers to Fair Access Assessment” Protocol
In brief: anticompetitive agreements in the pharmaceutical sector in USA
Snapshot: anticompetitive unilateral conduct in the pharmaceutical sector in USA
Mark Cuban's generic drug prices would save Medicare billions of dollars: Harvard study
Washington ups pressure on PBMs with more aggressive FTC policy, congressional ask for GAO study